Nanoform has appointed Eric Peter and Sergie Letser to drive the company’s business development in the US.
The expansion to Nanoform’s commercial team will give the company a strengthened presence in the US market and enable a continued rate of rapid global growth, it states.
Eric Peter
Eric Peter will utilize his business development and technical sales expertise gained through more than 25 years’ experience in the pharmaceutical industry. This includes over 10 years’ experience dedicated towards addressing poor solubility and permeability issues surrounding many new drug product candidates entering the clinical development phase. Eric has a proven track record of negotiating complex agreements and contracts to a successful conclusion, having effectively led commercial development for Patheon Inc and the US division of global pharma and particle engineering company, Hovione LLC.
“I am thrilled to be joining such a vibrant team that is dedicated to revolutionizing pharmaceutical development. I look forward to introducing Nanoform’s award-winning technology to partners in the US and working with them to solve their complex formulation challenges,” says Eric Peter.
Sergie Letser
Pharma BD professional, Sergie Letser, will also leverage his broad experience in pharmaceutical development and manufacturing to strengthen Nanoform’s commercial organisation. Sergie has expertise in lead generation and contract negotiation, having been responsible for driving US business development activities at pharma organisations, including Porton Pharma Solutions, Ltd, Johnson Matthey and Cambridge Major Laboratories.
“Nanoform has developed an outstanding technology that will enable pharmaceutical and biotechnology companies to significantly increase the solubility and bioavailability of their drugs. I anticipate exciting times ahead, working with the rest of the commercial development team to bring next-generation pharmaceutical products to the market,” says Sergie Letser.
Nanoform USA Inc
The two US-based appointments follow the establishment of Nanoform USA Inc., a wholly owned subsidiary in the US earlier this year, and the launch of an Initial Public Offering (IPO) on the Nasdaq First North Premier Growth Markets in Finland & Sweden.
Photo of Eric Peter and Sergie Letser
